Primary Arterial Hypertension and Drug-Induced Hypertension in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review

被引:10
|
作者
Gaman, Mihnea-Alexandru [1 ,2 ]
Kipkorir, Vincent [3 ]
Srichawla, Bahadar S. [4 ]
Dhali, Arkadeep [5 ]
Gaman, Amelia Maria [6 ,7 ]
Diaconu, Camelia Cristina [1 ,8 ]
机构
[1] Carol Davila Univ Med & Pharm, Fac Med, Bucharest 050474, Romania
[2] Fundeni Clin Inst, Ctr Hematol & Bone Marrow Transplantat, Dept Hematol, Bucharest 022328, Romania
[3] Univ Nairobi, Dept Human Anat & Physiol, Nairobi 30197, Kenya
[4] UMass Chan Med Sch, Dept Neurol, Worcester, MA 01655 USA
[5] Nottingham Univ Hosp NHS Trust, Dept Internal Med, Nottingham NG7 2UH, England
[6] Univ Med & Pharm Craiova, Dept Pathophysiol, Craiova 200349, Romania
[7] Filantropia City Hosp, Clin Hematol, Craiova 200143, Romania
[8] Clin Emergency Hosp Bucharest, Dept Internal Med, Bucharest 105402, Romania
关键词
myeloproliferative neoplasms; polycythemia vera; essential thrombocythemia; primary myelofibrosis; hypertension; blood pressure; cardiovascular risk factors; thrombosis; antihypertensive agents; drug-induced hypertension; CELL-FREE HEMOGLOBIN; ESSENTIAL THROMBOCYTHEMIA; RISK-FACTORS; POLYCYTHEMIA-VERA; THROMBOTIC COMPLICATIONS; OXIDATIVE STRESS; ANAGRELIDE TREATMENT; CONSECUTIVE PATIENTS; FEMALE-PATIENTS; JAK2; V617F;
D O I
10.3390/biomedicines11020388
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The impact of primary arterial hypertension (HTN) in myeloproliferative neoplasms (MPNs) remains unclear, with scant literature available, mostly focusing on cardiovascular risk factors as a singular entity or on organ-specific HTN. Furthermore, available studies reporting findings on drug-induced HTN in MPNs report varying and contradictory findings. In consideration of the above, this study set out to systematically review the available literature and shed light on the occurrence of HTN in MPNs, its association with thrombosis, as well as the drugs used in MPN management that could increase blood pressure. The literature search yielded 598 potentially relevant records of which 315 remained after the duplicates (n = 283) were removed. After we screened the titles and the abstracts of these publications, we removed irrelevant papers (n = 228) and evaluated the full texts of 87 papers. Furthermore, 13 records did not meet the inclusion criteria and were excluded from the systematic review. Finally, a total of 74 manuscripts were entered into the qualitative synthesis and included in the present systematic review. Our systematic review highlights that HTN is the most common comorbidity encountered in MPNs, with an impact on both the occurrence of thrombosis and survival. Moreover, drug-induced HTN remains a challenge in the management of MPNs. Further research should investigate the characteristics of patients with MPNs and HTN, as well as clarify the contribution of HTN to the development of thrombotic complications, survival and management in MPNs. In addition, the relationship between clonal hematopoiesis of indeterminate potential, HTN, cardiovascular disease and MPNs requires examination in upcoming assessments.
引用
收藏
页数:29
相关论文
共 50 条
  • [1] Drug-Induced Hypertension in Classical Philadelphia-Negative Myeloproliferative Neoplasms MPNs): Systematic Review
    Gaman, Mihnea-Alexandru
    Gaman, Amelia Maria
    Diaconu, Camelia Cristina
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S323 - S323
  • [2] CLINICAL FEATURES OF PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS COMPLICATED BY PORTAL HYPERTENSION
    Yan, M.
    Geyer, H.
    Mesa, R.
    Atallah, E.
    Callum, J.
    Bartoszko, J.
    Wong, F.
    Maganti, M.
    Yee, K.
    Gupta, V.
    [J]. HAEMATOLOGICA, 2013, 98 : 344 - 344
  • [3] Evaluation of thrombin generation in classical Philadelphia-negative myeloproliferative neoplasms
    Olteanu, Ariela Ligia
    Mihaila, Romeo-Gabriel
    Mihalache, Manuela
    [J]. REVISTA ROMANA DE MEDICINA DE LABORATOR, 2016, 24 (03): : 279 - 289
  • [4] Pediatric Philadelphia-Negative Myeloproliferative Neoplasms in the Era of WHO Classification: A Systematic Review
    Al-Mashdali, Abdulrahman F.
    Aldapt, Mahmood B.
    Rahhal, Alaa
    Hailan, Yousef M.
    Elhakeem, Israa
    Ali, Elrazi A.
    Rozi, Waail
    Yassin, Mohamed A.
    [J]. DIAGNOSTICS, 2023, 13 (03)
  • [5] Liquid Biopsy and Potential Liquid Biopsy-Based Biomarkers in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review
    Gaman, Mihnea-Alexandru
    Cozma, Matei-Alexandru
    Dobrica, Elena-Codruta
    Cretoiu, Sanda Maria
    Gaman, Amelia Maria
    Diaconu, Camelia Cristina
    [J]. LIFE-BASEL, 2021, 11 (07):
  • [6] Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities
    Coltro, Giacomo
    Loscocco, Giuseppe G.
    Vannucchi, Alessandro M.
    [J]. CELLULAR AND MOLECULAR ASPECTS OF MYELOPROLIFERATIVE NEOPLASMS - PT A, 2021, 365 : 1 - 69
  • [7] Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
    Helbig, Grzegorz
    [J]. MEDICAL ONCOLOGY, 2018, 35 (09)
  • [8] Drug-induced pulmonary arterial hypertension: a review
    Lohit Garg
    Ghulam Akbar
    Sahil Agrawal
    Manyoo Agarwal
    Leila Khaddour
    Rishin Handa
    Aakash Garg
    Mahek Shah
    Brijesh Patel
    Bhavinkumar D. Dalal
    [J]. Heart Failure Reviews, 2017, 22 : 289 - 297
  • [9] Drug-induced pulmonary arterial hypertension: a review
    Garg, Lohit
    Akbar, Ghulam
    Agrawal, Sahil
    Agarwal, Manyoo
    Khaddour, Leila
    Handa, Rishin
    Garg, Aakash
    Shah, Mahek
    Patel, Brijesh
    Dalal, Bhavinkumar D.
    [J]. HEART FAILURE REVIEWS, 2017, 22 (03) : 289 - 297
  • [10] Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
    Grzegorz Helbig
    [J]. Medical Oncology, 2018, 35